EPO and breast cancer: On the other hand, co-injection of a neutralizing anti-EPO antibody and rhEPO or targeting endogenous EPO using sEPOR inhibits the initiation of tumor angiogenesis of rat R3230-GFP mammary tumor cells and leads to growth delays during the initial stages of tumorigenesis.